Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

Samankaltaisia teoksia

• Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
  Tekijä: Sam, Johannes, et al.
  Julkaistu: (2020)
• Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model
  Tekijä: Cremasco, Floriana, et al.
  Julkaistu: (2021)
• CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
  Tekijä: Bacac, Marina, et al.
  Julkaistu: (2016)
• From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
  Tekijä: Mouw, Kent W., et al.
  Julkaistu: (2018)
• Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
  Tekijä: Kobold, Sebastian, et al.
  Julkaistu: (2018)